Mostrar el registro sencillo del ítem

Somatostatin receptor ligands induce TSH deficiency in thyrotropin-secreting pituitary adenoma

dc.rights.licenseopenen_US
dc.contributor.authorILLOUZ, F.
dc.contributor.authorCHANSON, P.
dc.contributor.authorSONNET, E.
dc.contributor.authorBRUE, T.
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorFERRIERE, Amandine
dc.contributor.authorSANSON, M.-L.R.
dc.contributor.authorVANTYGHEM, M.-C.
dc.contributor.authorRAVEROT, G.
dc.contributor.authorMUNIER, M.
dc.contributor.authorRODIEN, P.
dc.contributor.authorBRIET, C.
dc.date.accessioned2022-04-11T13:38:25Z
dc.date.available2022-04-11T13:38:25Z
dc.date.issued2021-01
dc.identifier.issn1479-683Xen_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/136626
dc.description.abstractEnObjective: Somatostatin receptor ligands (SRL) are useful to control central hyperthyroidism in patients with thyrotropin-secreting pituitary adenoma (TSH pituitary adenoma). The aim of this study was to describe the frequency of thyrotropin deficiency (TSH deficiency) in patients with TSH pituitary adenoma treated by SRL. Design: Retrospective study. Methods: Patients with central hyperthyroidism due to TSH pituitary adenoma treated by short or long-acting SRL were retrospectively included. TSH deficiency was defined by a low FT4 associated with non-elevated TSH concentrations during SRL therapy. We analysed the frequency of TSH deficiency and the characteristics of patients with or without TSH deficiency. Results: Forty-six patients were included. SRL were used as the first-line therapy in 21 of 46 patients (46%). Central hyperthyroidism was controlled in 36 of 46 patients (78%). TSH deficiency appeared in 7 of 46 patients (15%) after a median time of 4 weeks (4-7) and for a median duration of 3 months (2.5-3). The TSH deficiency occurred after one to three injections of long-acting SRL used as first-line therapy in 6/7 cases. There were no differences in terms of clinical and hormonal features, size of adenomas or doses of SRL between patients with or without TSH deficiency. Conclusions: SRL can induce TSH deficiency in patients with central hyperthyroidism due to TSH pituitary adenoma. Thyrotropic function should be assessed before the first three injections of SRL in order to track TSH deficiency and reduce the frequency of injections when control of thyrotoxicosis rather than tumour reduction is the aim of the treatment.
dc.language.isoENen_US
dc.title.enSomatostatin receptor ligands induce TSH deficiency in thyrotropin-secreting pituitary adenoma
dc.title.alternativeEur J Endocrinolen_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1530/EJE-20-0484en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed33112257en_US
bordeaux.journalEuropean journal of endocrinologyen_US
bordeaux.page1-8en_US
bordeaux.volume184en_US
bordeaux.hal.laboratoriesNeurocentre Magendie - UMR-S 1215en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=European%20journal%20of%20endocrinology&rft.date=2021-01&rft.volume=184&rft.issue=1&rft.spage=1-8&rft.epage=1-8&rft.eissn=1479-683X&rft.issn=1479-683X&rft.au=ILLOUZ,%20F.&CHANSON,%20P.&SONNET,%20E.&BRUE,%20T.&FERRIERE,%20Amandine&rft.genre=article


Archivos en el ítem

ArchivosTamañoFormatoVer

No hay archivos asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem